Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss drugs flood IndiaCNBC • 04/10/26
Novo Nordisk (NVO) Increases Yet Falls Behind Market: What Investors Need to KnowZacks Investment Research • 04/08/26
Trump's Iran deadline, the Altman-Musk feud, Novo's Wegovy pill and more in Morning SquawkCNBC • 04/07/26
Novo Nordisk's explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatmentCNBC • 04/07/26
Novo Nordisk Shares Down 43% in a Year as Generic Rivals Force 48% Price Cuts24/7 Wall Street • 04/03/26
Trump threatens 100% tariff on US drug makers that don't strike deals to lower pricesThe Guardian • 04/02/26
Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugsCNBC • 04/02/26
How Novo Nordisk Is Striking Back As Eli Lilly Plans Its Newest Weight-Loss LaunchInvestors Business Daily • 04/02/26
GLP-1 wars: Lilly's FDA-approved oral weight-loss pill puts Novo Nordisk's Wegovy franchise under fresh pressureProactive Investors • 04/02/26
Novo Nordisk says Wegovy pill outperforms Lilly's oral GLP-1 in cross-trial comparisonCNBC • 04/02/26
Wall Street sees multi-billion dollar debut for Lilly's obesity pill despite Novo leadReuters • 04/02/26